Fabienne Mackay
Professor Fabienne Mackay obtained her PhD from Louis Pasteur University, Strasbourg, France. She is Inaugural Head, School of Biomedical Sciences. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia. Her laboratory helped the BAFF inhibitor approved by the FDA in 2011: first new treatment for lupus in over 50 years. first new treatment for lupus in over 50 years. Prof Mackay’s group is focusing on inhibitors for the BAFF receptor TACI to treat Systemic Lupus Erythematosus and Chronic Lymphocytic Leukaemia without compromising key immune function and, therefore, an approach that has a better safety profile. Her research and teaching directly influence clinical practice and continues to make internationally significant contributions to the field of autoimmunity and oncology, with a strong record of knowledge translation and community engagement. She is a Council Member, International Cytokine & Interferon Society and Fellow, Australian Academy of Health and Medical Sciences.
Abstracts this author is presenting: